XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Nasdaq IPO Fund Managers turning XRX in Piss'Doff Pharma

<< Previous

Bullboard Posts

Next >>

Comment by ACTIONKon Nov 25, 2021 8:54am

86 Views

Post# 34164626

RE:Nasdaq IPO Fund Managers turning XRX in Piss'Doff Pharma

When looking at a company there are many things to consider when investing, or if you are a gamblier just make noise and call people names.

When reviewing this company as a whole - it currently sits at a valuation of $6.58 per share. With a EPS/P/E at 0.87 and 5 respectively. the earnings yield (EY) at 20%. This is a super cheap company (~50% sale) and if you haven't been buying in you may be kicking yourself in the future.

Investing with confidence.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market